• Gene One Life Science set an early repurchase of KRW 2.5 billion of its 6th private convertible bonds.
• Total cash outlay set at KRW 2.6 billion, reflecting principal and interest; payment scheduled for Nov. 4, 2026.
• Transaction triggered by a bondholder put option; repurchase to be funded from internal cash.
• Bonds carry a conversion price of KRW 10,960; full conversion would issue 228,102 common shares, equal to 1.25%.
• Outstanding principal balance expected to fall to KRW 500 million following the buyback.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007000497), on October 07, 2026, and is solely responsible for the information contained therein.